Quantcast
Home > Quotes > AUTL

Autolus Therapeutics plc American Depositary Share (AUTL) Quote & Summary Data

AUTL 
$36.88
*  
0.12
0.32%
Get AUTL Alerts
*Delayed - data as of Nov. 15, 2018 10:21 ET  -  Find a broker to begin trading AUTL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AUTL Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 35 / $ 37
1 Year Target
38
Today's High / Low
$ 36.88 / $ 36.57
Share Volume
711
50 Day Avg. Daily Volume
54,121
Previous Close
$ 37
52 Week High / Low
$ 53.24 / $ 19.1733
Market Cap
1,480,875,943
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.27

Intraday Chart

Shares Traded

Share Volume:
711
50 Day Avg. Daily Volume:
54,121

Trading Range

The current last sale of $36.88 is 92.35% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 36.88 $ 53.24
 Low: $ 36.57 $ 19.1733

Company Description (as filed with the SEC)

We are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. We believe our programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. Cancers thrive on their ability to fend off T cells by evading recognition by T cells and by establishing other defense mechanisms, such as checkpoint inhibition and creating a hostile microenvironment.  ... More ...  


Risk Grade

Where does AUTL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 36.57
Open Date:
Nov. 15, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x